Madam Chair, can the minister share more about what can be done in working with provinces and territories to address this seeming gap? The issue, it seems, is that Noor cannot access the drug because it is approved by Health Canada but not listed by the Canadian drug agency as recommended for public coverage.
Can he share more, just briefly, about what can be done in working with provinces and territories to address this?